the upper bound is also below the null, so we could interpret this to indicate that the new drug is safer than the comparator with respect to the null threshold. We could also consider using another threshold to the left of the null threshold for determining
whether the new drug is meaningfully safer than the comparator. Scenario F is one in which no safety statement can be made and in which continued monitoring is warranted.